Related Experiment Video
Updated: Jun 22, 2026
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
Published on: July 22, 2020
Reduced NGF secretion by HT-29 human colon cancer cells treated with a GRPR antagonist
Caroline Brunetto de Farias1, Laura Stertz, Rodrigo Cruz Lima
1Cancer Research Laboratory, Academic Hospital Research Center, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
Abstract:
The gastrin-releasing peptide receptor (GRPR) is a therapeutic target in colon cancer. Here we show that the GRPR antagonist RC-3095 (10(-3), 10(-6), or 1 microM) decreases nerve growth factor (NGF) secretion measured by enzyme-linked immunosorbent assay (ELISA) in HT-29 human colon carcinoma cells. The results suggest that decreased secretion of neurotrophins might be a novel mechanism by which GRPR antagonists exert their antiproliferative effects in cancer cells.
Insights
The gastrin-releasing peptide receptor (GRPR) antagonist RC-3095 reduces nerve growth factor (NGF) secretion in colon cancer cells. This suggests a new way GRPR antagonists may slow cancer growth.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- The gastrin-releasing peptide receptor (GRPR) is implicated in colon cancer progression.
- Targeting GRPR offers a potential therapeutic strategy for colon cancer treatment.
Purpose of the Study:
- To investigate the effect of the GRPR antagonist RC-3095 on nerve growth factor (NGF) secretion in human colon carcinoma cells.
- To explore potential mechanisms of antiproliferative effects of GRPR antagonists.
Main Methods:
- Utilized HT-29 human colon carcinoma cells.
- Administered the GRPR antagonist RC-3095 at concentrations of 10(-3), 10(-6), and 1 microM.
- Quantified nerve growth factor (NGF) secretion using enzyme-linked immunosorbent assay (ELISA).
Main Results:
- RC-3095 significantly decreased NGF secretion in HT-29 cells.
- The reduction in NGF secretion was observed across tested concentrations of RC-3095.
Conclusions:
- Decreased neurotrophin secretion, specifically NGF, may be a novel mechanism underlying the antiproliferative action of GRPR antagonists.
- These findings highlight a potential new therapeutic avenue targeting GRPR signaling in colon cancer.
